CXS 6001
Latest Information Update: 16 Jul 2016
At a glance
- Originator ChemGenex Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 21 Jun 2004 AGT Biosciences has merged with ChemGenex Therapeutics Inc to form ChemGenex Pharmaceuticals
- 15 Apr 2002 Preclinical trials in Cancer in USA (PO)